US Stock Market Closed

Dashboard

Vir Biotechnology, Inc. (VIR)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

H

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

CEO

George A. Scangos

Employees

229

Industry

Infectious Disease Biopharmaceuticals

Sector

Healthcare

Headquarters

San Francisco

Exchange

NASDAQ

Summary Stats

Market Cap

3.98B

Revenue

2.38B

Net Income

1.14B

EPS

$8.46

Price-to-Earnings

3.54

Price-to-Book

1.85

Debt-to-Equity

0.25

News

Analyst Ratings

Price targets projected by 7 analysts

High

$100.00

Average

$54.86

Low

$24.00

Ratings calculated by 8 analysts

Buy

6

Hold

1

Sell

1

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Not Available

Actual

$1.30 -

Consensus

-

Report Date

Year Ago

0.82

Year Ago Change %

Up 58%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites